AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35610297
Drug: Commercial activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial activity tracker bracelet with daily activity goal and inactivity alerts for 12 months
Trial: 616774613
Drug: Endoscopic concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic concurrent therapy
Trial: 616774613
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (Control)
Trial: 32463470
Drug: Bupropion (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150 mg for 4 weeks plus 300 mg for 8 weeks)
Trial: 36280809
Drug: ECD program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECD program with monthly developmental feedback
Trial: 33169672
Drug: Tezepelumab (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (70 mg every 4 weeks, 210 mg every 4 weeks, or 280 mg every 2 weeks)
Trial: 32103903
Drug: Cefotetan disodium
RxNorm normalized name: Cefotetan Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan disodium 1.0 g BID for 7 days
Trial: 32915004
Drug: Control (listing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (listing daily activities and reflecting on obstacles and benefits)
Trial: 35381421
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at 25 µg/min
Trial: 34152206
Drug: Conidial suspension
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conidial suspension (106 conidia mL‐1) of Fusarium oxysporum isolates, applied by pouring 50 ml per pot.
Trial: 34152206
Drug: Sterile distilled
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile distilled water (control) applied by pouring 50 ml per pot.
Trial: 33993273
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (β‐lactam plus aminoglycoside or quinolone)
Trial: 33993273
Drug: Monotherapy (β‐lactam)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (β‐lactam)
Trial: 32667636
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (clinician's choice, CC)
Trial: 32923335
Drug: Tablet-based worked
RxNorm normalized name: Apis cerana worker secretion preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based worked examples (G2)
Trial: 35765103
Drug: UC-MSCs (1 × [Formula:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSCs (1 × [Formula: see text] cells/kg BW per injection) every other day for three injections
Trial: 33176886
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h (Group B)
Trial: 33176886
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate at 4 mmol/L (Group A - control)
Trial: 35485381
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg subcutaneously plus standard of care (group A)
Trial: 35485381
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg subcutaneously (group A)
Trial: 33538248
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day
Trial: 32219884
Drug: Double-blind, placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind, placebo-controlled oral food challenges (DBPCFC)
Trial: 33424840
Drug: PEG‐IFNα‐2b therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2b therapy
Trial: 33424840
Drug: Anti‐CD24 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐CD24 antibody treatment
Trial: 32073648
Drug: Tivantinib (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (360 mg twice daily) plus Cetuximab (500 mg/m2 every 2 weeks)
Trial: 32073648
Drug: Cetuximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (500 mg/m2 every 2 weeks)
Trial: 32073648
Drug: Tivantinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib monotherapy
Trial: 35017288
Drug: Traditional Treatment
RxNorm normalized name: Midol Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Treatment (TM)
Trial: 36122589
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicines (IHMs) in fifty‐millesimal (LM) potencies
Trial: 34316017
Drug: Midostaurin in
RxNorm normalized name: Product containing midostaurin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin in addition to intensive chemotherapy
Trial: 32826637
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) therapy for 3 min
Trial: 35149574
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of progestogen only pill (POP) with emergency contraception (EC) from pharmacies as routine practice
Trial: 36206498
Drug: Toripalimab 240
RxNorm normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240 mg plus chemotherapy
Trial: 36206498
Drug: Toripalimab 240
RxNorm normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240 mg plus chemotherapy with high tumor mutational burden
Trial: 36206498
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy with high tumor mutational burden
Trial: 36206498
Drug: Toripalimab 240
RxNorm normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240 mg plus chemotherapy with mutations in the focal adhesion-PI3K-Akt signaling pathway
Trial: 36075242
Drug: Pirfenidone (2403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (2403 mg daily)
Trial: 36296958
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + high-protein diet (1.2-1.5 g/kg)
Trial: 36296958
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + high-protein and omega-3-enriched diet (2.2 g/day)
Trial: 33462825
Drug: Acarbose tablet
RxNorm normalized name: Acarbose Tablets
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose tablet (50 mg and 100 mg) administered by chewing
Trial: 33462825
Drug: Acarbose tablet
RxNorm normalized name: Acarbose Tablets
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose tablet (50 mg and 100 mg) administered by swallowing
Trial: 34648425
Drug: Self-monitoring followed
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring followed by CBT-I concurrent with PAP
Trial: 32019736
Drug: PRBCs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRBCs with Hb content ≥50 g (Group I, n = 80)
Trial: 35598427
Drug: Against Stigma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Against Stigma Program (60-minute weekly sessions for 6 weeks)
Trial: 35598427
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (Control group)
Trial: 34747087
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (Hb transfusion threshold <75 g/L)
Trial: 34747087
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hb <95 g/L for operating room or ICU; <85 g/L for ward)
Trial: 33148667
Drug: PIPAC oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIPAC oxaliplatin at 45 mg/m2
Trial: 33148667
Drug: PIPAC oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIPAC oxaliplatin at 90 mg/m2
Trial: 33148667
Drug: PIPAC oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIPAC oxaliplatin at 120 mg/m2
Trial: 33148667
Drug: PIPAC oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIPAC oxaliplatin (all doses)
Trial: 36102593
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Therapy (VRT)
Trial: 33165566
Drug: Inactivated Influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Influenza Vaccine (IIV3)
Trial: 33165566
Drug: Inactivated Poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Poliovirus Vaccine (IPV)
Trial: 33138797
Drug: Additive models
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additive models in edgeR for pre- and post-treatment groups
Trial: 32035552
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg bimekizumab
Trial: 32035552
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg bimekizumab
Trial: 32035552
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg bimekizumab with a one-off 320 mg loading dose
Trial: 32035552
Drug: Bimekizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (all doses combined)
Trial: 34103066
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (30 mg/kg/day)
Trial: 35607975
Drug: Daily written
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily written updates on the satisfaction and psychologic symptoms of families of ICU patients
Trial: 33821928
Drug: Minimal Contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Contact Cognitive Behavioral Therapy (MC-CBT)
Trial: 33821928
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Behavioral Therapy (S-CBT)
Trial: 33357641
Drug: sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 200 mg twice-daily
Trial: 33357641
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg twice-daily
Trial: 34473295
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 4000 IU daily for 24 months
Trial: 34264296
Drug: Combined Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined Atropine and Patching Therapy (CAPT)
Trial: 34286560
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg plus nutritional supplement (Panax ginseng, Moringa Oleifera, Rutin) once daily for 3 months
Trial: 34286560
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg plus placebo once daily for 3 months
Trial: 32668113
Drug: Roflumilast 0.3%
RxNorm normalized name: ROFLUMILAST 0.3% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 0.3% cream
Trial: 32668113
Drug: Roflumilast 0.15%
RxNorm normalized name: ROFLUMILAST 0.15% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 0.15% cream
Trial: 32668113
Drug: Roflumilast 0.3%
RxNorm normalized name: ROFLUMILAST 0.3% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 0.3% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Trial: 32668113
Drug: Roflumilast 0.15%
RxNorm normalized name: ROFLUMILAST 0.15% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 0.15% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Trial: 32668113
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Trial: 35286526
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Trial: 36271950
Drug: 200-mg ibuprofen
RxNorm normalized name: ibuprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg ibuprofen
Trial: 36271950
Drug: 600-mg ibuprofen
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg ibuprofen
Trial: 36071224
Drug: Genomic analyses
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic analyses to target therapy
Trial: 38566240
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (exact dosage and duration not specified)
Trial: 33215762
Drug: Nilotinib 150
RxNorm normalized name: nilotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib 150 mg
Trial: 33215762
Drug: Late-start nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late-start nilotinib 150 mg
Trial: 33215762
Drug: Nilotinib 150
RxNorm normalized name: nilotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib 150 mg vs 300 mg
Trial: 35106880
Drug: 26 μg
RxNorm normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 26 μg LSD
Trial: 35106880
Drug: 13 μg
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13 μg LSD
Trial: 32986363
Drug: Cervical cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical cancer treatment modalities (radiotherapy, brachytherapy, chemotherapy, surgery)
Trial: 32036491
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg daily on days 2-4)
Trial: 32036491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard triplet regimen comprising aprepitant, a 5-HT3 receptor antagonist, and dexamethasone 7.5 mg on days 2-4)
Trial: 35567836
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose corticosteroids
Trial: 33374524
Drug: Encapsulated dry
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated dry maté extract providing 580 mg of caffeoyl quinic acid derivatives (CQAs) daily
Trial: 32740481
Drug: E2/P4 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/P4 (all doses)
Trial: 33852195
Drug: Isocaloric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric glucose (GLU) administration
Trial: 33856589
Drug: Resective surgery
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resective surgery with the insertion of HAM patch (Group A)
Trial: 35365582
Drug: tofacitinib in
RxNorm normalized name: Product containing tofacitinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib in the Oral Psoriatic Arthritis TriaL program
Trial: 36116927
Drug: Recombinant poly-epitope
RxNorm normalized name: Recombinant chimeric COVID-19 epitope DC vaccine;
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant poly-epitope vaccine EgG1Y162-2 (4)
Trial: 34156639
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with 50 mg/kg zinc acetate (T1)
Trial: 34156639
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with 200 mg/kg zinc acetate (T2)
Trial: 34156639
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with 300 mg/kg zinc acetate (T3)
Trial: 34807723
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid administration deemed inappropriate
Trial: 32459282
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (RS) supplementation (16 g/day for four weeks)
Trial: 87266332
Drug: Cefuroxime (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (two-dose peroperative regimen)
Trial: 36008082
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (Methylprednisolone)
Trial: 32758282
Drug: Propolis tablet
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis tablet (450 mg, containing 100 mg polyphenol compounds), twice daily for 6 weeks
Trial: 32758282
Drug: Identical placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo, twice daily for 6 weeks
Trial: 34487871
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional laser-assisted photodynamic therapy (AFL-PDT)
Trial: 32729954
Drug: Acellular dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular dermal matrix (ADM) treatment
Trial: 34688699
Drug: Teprotumumab treatment
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teprotumumab treatment (8 infusions over 24 weeks)
Trial: 34688699
Drug: Teprotumumab re-treatment
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teprotumumab re-treatment
Trial: 34688699
Drug: Teprotumumab treatment
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teprotumumab treatment
Trial: 34587702
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy alone
Trial: 34277982
Drug: Hypoglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemic clamp (2.2-2.5 mmol/L)
Trial: 34277982
Drug: Euglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemic clamp (4.5-5.5 mmol/L)
Trial: 32410519
Drug: Suction and
RxNorm normalized name: TUBING,SUCTION AND FILTER KIT DEVILBISS #18600-KITN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suction and local steroid injection (Group B)
Trial: 33216167
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg/24 h, transdermally)
Trial: 33216167
Drug: Mecamylamine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (7.5 mg, p.o.)
Trial: 34902004
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate, 50 μg, with placebo, 2 puffs twice daily for 12 weeks
Trial: 34902004
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) - fluticasone propionate, 50 μg, with salmeterol, 25 μg, 2 puffs twice daily for 12 weeks
Trial: 32361959
Drug: Underwater weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwater weight bath traction therapy and NSAIDs
Trial: 33638928
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Er: YAG laser and autologous platelet-rich plasma (PRP)
Trial: 33297866
Drug: Alteplase at
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase at 0.6 mg/kg intravenously
Trial: 32317109
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release therapy (5 sessions over 2 weeks)
Trial: 32317109
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program (10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation over 2 weeks)
Trial: 37853420
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release therapy